BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
1. BCRX reported Q1 2025 sales of $145.50 million, up 52.7% YoY. 2. Orladeyo's revenue increased to $134.2 million, contributing significantly. 3. Net income turned positive at $32 thousand, contrasting last year's loss. 4. 2025 Orladeyo revenue guidance increased to $580-$600 million. 5. Stock price rose 23.5% to $11.03 following the earnings report.